在加纳土著人中发展雷暴相关喘的风险因素:一项匹配的病例控制研究
Hephzibah Okyere-Mensah1, Joshua Arthur1, Ruth Owusu1
1Public Health Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
Public health in practice (Oxford, England)
|July 23, 2024
概括
加纳的雷暴喘 (TA) 与过敏史有关,这是一个重要的风险因素. 虽然喘病史显示了相关性,但它
科学领域:
- 公共卫生 公共卫生
- 流行病学 流行病学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 流行性雷暴喘 (TA) 构成了重大的公共卫生挑战,可能压倒医疗保健系统.
- 迦纳首次记录的AT发病例需要了解其在当地人口中独特的风险因素.
研究的目的:
- 在加纳调查与雷暴喘 (TA) 相关的慢性呼吸道风险因素.
- 确定加纳确定的TA风险因素是否与全球其他地区观察到的风险因素一致.
主要方法:
- 一个匹配的病例控制研究在加纳阿尚蒂地区进行.
- 来自41个病例和82个对照组的数据使用千平方和多重逻辑回归进行了分析.
- 对患者的病历进行了审查,以查看人口统计信息,过敏史和喘史.
主要成果:
- 过敏史是雷暴喘的一个显著风险因素 (AOR = 12.48,p = 0.05).
- 喘病史与TA相关 (AOR = 4.53,p = 0.064) 但没有达到统计学意义的风险因素.
- 29.3%的TA病例和1.2%的对照报告过敏史.
结论:
- 之前的过敏史是加纳雷暴喘发展的关键预测因素.
- 虽然喘病史是相关的,但在本研究中,喘并不是统计学上显著的风险因素.
- 对TA风险因素的认识对于有效的健康教育,患者管理和准备至关重要.
相关概念视频
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Asthma: Pathogenesis and Management
380
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
380
Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Other Pulmonary Disorders
810
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
810


